AARDVARK THERAPEUTICS INC. - COMMON STOCK

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

10 Dec 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

25 Nov 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

13 Nov 2025 16:05:02 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

11 Nov 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

04 Nov 2025 12:00:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 Nov 2025 17:55:39 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

03 Nov 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

22 Oct 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

08 Oct 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

23 Sep 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

04 Sep 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

27 Aug 2025 16:10:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

13 Aug 2025 16:10:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

12 Aug 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

18 Jul 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

24 Jun 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

19 May 2025 16:10:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

14 May 2025 16:10:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

07 May 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

31 Mar 2025 16:10:00 بحسب Nasdaq GlobeNewswire